⏳ Venous Thromboembolism Anticoagulation Duration Decision
This tool decides whether VTE anticoagulation stops at 3 months or extends, weighing recurrence risk (by provoking factor) against bleeding risk.
Unprovoked VTE tips toward extended anticoagulation unless bleeding risk is high, where a 3-month course with possible aspirin is preferred. (original synthesis · not guideline verbatim)
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use to set anticoagulation duration: short course for major transient triggers, indefinite for cancer or recurrence, and bleeding-risk-dependent for unprovoked VTE.
How it works
Major transient → 3 months. Minor transient → ≥ 3 months, individualized. Cancer → until inactive. Recurrent → extended/indefinite. Unprovoked → extended if low-moderate bleeding (reduced-dose DOAC), stop at 3 months if high bleeding.
Key points
- Unprovoked VTE tips toward extended anticoagulation unless bleeding risk is high, where a 3-month course with possible aspirin is preferred. (original synthesis · not guideline verbatim)
- All VTE receives at least 3 months of anticoagulation regardless of provoking factor.
- Extended courses are periodically reassessed for bleeding risk, benefit, and preference.
References
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Provoking-factor type | Major transient (surgery/trauma/prolonged immobilization) |
|---|---|
| Bleeding risk | Low-moderate |
→Anticoagulation durationStop anticoagulation after 3 months
- Decision：Caused by a major transient factor (surgery, trauma, prolonged immobilization), the recurrence risk after stopping is low, and 3 months suffices.
- General rule：All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference
- Bleeding risk：Low-moderate bleeding risk: can tolerate extended anticoagulation
| Provoking-factor type | Recurrent VTE |
|---|---|
| Bleeding risk | High |
→Anticoagulation durationExtended/indefinite anticoagulation
- Decision：Recurrent VTE (especially unprovoked) carries high recurrence risk, and extended or indefinite anticoagulation is recommended.
- General rule：All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference
- Bleeding risk：High bleeding risk: favors a fixed 3-month course
Frequently asked questions
- What is Venous Thromboembolism Anticoagulation Duration Decision?
- This tool decides whether VTE anticoagulation stops at 3 months or extends, weighing recurrence risk (by provoking factor) against bleeding risk.
- How is Venous Thromboembolism Anticoagulation Duration Decision calculated? What is the core formula?
- Major transient → 3 months. Minor transient → ≥ 3 months, individualized. Cancer → until inactive. Recurrent → extended/indefinite. Unprovoked → extended if low-moderate bleeding (reduced-dose DOAC), stop at 3 months if high bleeding.
- When is Venous Thromboembolism Anticoagulation Duration Decision used?
- Use to set anticoagulation duration: short course for major transient triggers, indefinite for cancer or recurrence, and bleeding-risk-dependent for unprovoked VTE.
- What are the key clinical points for Venous Thromboembolism Anticoagulation Duration Decision?
- Unprovoked VTE tips toward extended anticoagulation unless bleeding risk is high, where a 3-month course with possible aspirin is preferred. (original synthesis · not guideline verbatim) All VTE receives at least 3 months of anticoagulation regardless of provoking factor. Extended courses are periodically reassessed for bleeding risk, benefit, and preference.
- What are the limits and cautions when using Venous Thromboembolism Anticoagulation Duration Decision?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Venous Thromboembolism Anticoagulation Duration Decision calculated in practice? Can you show a worked example?
- Inputs: Provoking-factor type Major transient (surgery/trauma/prolonged immobilization), Bleeding risk Low-moderate → Result: Anticoagulation duration Stop anticoagulation after 3 months（Decision: Caused by a major transient factor (surgery, trauma, prolonged immobilization), the recurrence risk after stopping is low, and 3 months suffices., General rule: All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference, Bleeding risk: Low-moderate bleeding risk: can tolerate extended anticoagulation） Inputs: Provoking-factor type Recurrent VTE, Bleeding risk High → Result: Anticoagulation duration Extended/indefinite anticoagulation（Decision: Recurrent VTE (especially unprovoked) carries high recurrence risk, and extended or indefinite anticoagulation is recommended., General rule: All VTE is anticoagulated at least 3 months; those on extended anticoagulation should periodically (e.g. yearly) reassess bleeding risk, benefit, and patient preference, Bleeding risk: High bleeding risk: favors a fixed 3-month course）